Perm Medical JournalPerm Medical JournalПермский медицинский журнал (сетевое издание "Perm medical journal")0136-14492687-1408Eco-Vector70442210.17816/pmj4345-19Literature reviewОбзор литературыReview ArticleMetabolic dysfunction-associated steatotic liver disease and cardiovascular pathologyАссоциированная с метаболической дисфункцией стеатотическая болезнь печени и сердечно-сосудистая патологияhttps://orcid.org/0000-0002-3920-8234GaisinIlshat R.ГайсинИльшат Равилевич
Russian Federation

DSc in Medicine, Associate Professor, Professor, Department of Hospital Therapy with Courses in Cardiology and Functional Diagnostics, Faculty of Advanced Training and Professional Retraining

доктор медицинских наук, доцент, профессор кафедры госпитальной терапии с курсами кардиологии и функциональной диагностики факультета повышения квалификации и профессиональной переподготовки

igaisin@mail.ruhttps://orcid.org/0009-0007-4051-665XKochurovEvgeny K.КочуровЕвгений Константинович
Russian Federation

Postgraduate Student, Department of Hospital Therapy with Courses in Cardiology and Functional Diagnostics, Faculty of Advanced Training and Professional Retraining

аспирант кафедры госпитальной терапии с курсами кардиологии и функциональной диагностики факультета повышения квалификации и профессиональной переподготовки

evg.konst@yahoo.comhttps://orcid.org/0009-0007-0100-1629LoshkarevEvgenii A.ЛошкаревЕвгений Андреевич
Russian Federation

Cardiologist, Acting Assistant, Department of Hospital Therapy with Courses in Cardiology and Functional Diagnostics, Faculty of Advanced Training and Professional Retraining

врач-кардиолог, исполняющий обязанности ассистента кафедры госпитальной терапии с курсами кардиологии и функциональной диагностики факультета повышения квалификации и профессиональной переподготовки

lzauva@mail.ruhttps://orcid.org/0009-0003-9275-6162GaleevAzat S.ГалеевАзат Сергеевич
Russian Federation

Endocrinologist

врач-эндокринолог

ellegaleev@yandex.ruhttps://orcid.org/0009-0002-7773-0805KholzodaSorbon A.ХолзодаСорбон Абдуалим
Russian Federation

Cardiologist

врач-кардиолог

sorbonkholzoda2000@gmail.comhttps://orcid.org/0000-0003-1683-4512GubaydullinaZukhra R.ГубайдуллинаЗухра Рифкатовна
Russian Federation

PhD in Medicine, Rheumatologist

кандидат медицинских наук, врач-ревматолог

zukhra.bagautdinova@yandex.ruIzhevsk State Medical UniversityИжевский государственный медицинский университетCity Polyclinic No. 1, IzhevskГородская поликлиника № 1, г. ИжевскNizhnekamsk Central District Multidisciplinary HospitalНижнекамская центральная районная многопрофильная больницаSadykov City Clinical Hospital No. 7Городская клиническая больница № 7 имени М.Н. Садыкова200920264345191703202605072026Copyright ©; 2026, Eco-VectorCopyright ©; 2026, Эко-Вектор2026Eco-VectorЭко-Векторhttps://eco-vector.com/for_authors.php#07https://permmedjournal.ru/PMJ/article/view/704422

The data on the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and its phenotypes, the evolution of steatotic liver disease terminology and its association with cardiovascular diseases were summarized. A systematic search for relevant publications in the PubMed database was performed.

MASLD has become one of the most prevalent and underappreciated cardiovascular threats. It is closely associated with the development and progression of atherosclerotic cardiovascular diseases, arrhythmias, conduction disorders, hypertension and heart failure. Moreover, MASLD is a crucial part of the cardiohepatorenal continuum. Raising awareness of MASLD among the general public and at-risk populations, unifying existing guidelines for cardiometabolic diseases, and the development of regional and global strategies to combat MASLD are essential to tackle the cardiometabolic pandemic.

Обобщены данные о распространенности метаболически-ассоциированной стеатотической болезни печени (МАСБП) и ее фенотипов, эволюции терминологии стеатотической болезни печени и ее взаимосвязях с сердечно-сосудистой патологией. Проведен систематический анализ релевантных публикаций в базе данных PubMed.

МАСБП стала одной из самых крупных и недооцененных сердечно-сосудистых угроз. МАСБП тесно ассоциирована с развитием и прогрессированием атеросклеротических сердечно-сосудистых заболеваний, нарушений ритма и проводимости, гипертензии и сердечной недостаточности. Более того, МАСБП является ключевым звеном кардиогепаторенального континуума. Повышение осведомленности о МАСБП в общей популяции и группах риска, унифицирование рекомендаций по кардиометаболическим заболеваниям и разработка региональных и глобальных стратегий по борьбе с МАСБП являются необходимыми условиями для преодоления кардиометаболической пандемии.

Metabolic dysfunction-associated steatotic liver diseaseMASLDatherosclerotic cardiovascular diseasesatrial fibrillationheart failurehypertensioncardiohepatorenal continuumМетаболически-ассоциированная стеатотическая болезнь печениМАСБПатеросклеротические сердечно-сосудистые заболеванияфибрилляция предсердийсердечная недостаточностьгипертензиякардиогепаторенальный континуумYounossi Z.M., Golabi P., Paik J.M. et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 2023; 77 (4): 1335–1347. DOI: 10.1097/HEP.0000000000000004Younossi Z.M., Golabi P., Paik J. et al. Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa. Liver Int. 2024; 44: 1061–1070. DOI: 10.1111/liv.15852Le M.H., Yeo Y.H., Zou B. et al. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. Clin Mol Hepatol. 2022; 28: 841–850. DOI: 10.3350/cmh.2022.0239Lee E.J., Choi M., Ahn S.B. et al. Prevalence of nonalcoholic fatty liver disease in pediatrics and adolescents: a systematic review and meta-analysis. World J Pediatr. 2024; 20: 569–580. DOI: 10.1007/s12519-024-00814-1Rinella M.E., Lazarus J.V., Ratziu V. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023; 79: 1542–1556. DOI: 10.1097/HEP.0000000000000520Eslam M., Newsome P.N., Sarin S.K. et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020; 73 (1): 202–209. DOI: 10.1016/j.jhep.2020.03.039Гайсин И.Р. Ассоциированная с метаболической дисфункцией жировая болезнь печени (МАЖБП) – новая нозологическая форма (обзор литературы). Здоровье, демография, экология финно-угорских народов 2021; 2: 58–62. / Gaisin I.R. Metabolic dysfunction-associated fatty liver disease (MAFLD) – a novel nosological unit (a literature review). Health, Demography, and Ecology of Finno-Ugric Peoples 2021; 2: 58–62 (in Russian).Гайсин И.Р., Кочуров Е.К. Поражение печени при псориатическом артрите: обзор литературы. Здоровье, демография, экология финно-угорских народов 2024; 4: 54–60. / Gaisin I.R., Kochurov E.K. Liver abnormalities in psoriatic arthritis: a literature review. Health, Demography, and Ecology of Finno-Ugric Peoples 2024; 4: 54–60 (in Russian).Гайсин И.Р., Кочуров Е.К., Лошкарев Е.А., Галеев А.С. Ассоциированная с метаболической дисфункцией стеатотическая болезнь печени (МАСБП) и лишняя масса тела: обзор литературы. Здоровье, демография, экология финно-угорских народов 2025; 3: 35–42. DOI: 10.64111/1994-8921.2025.51.3.007 / Gaisin I.R., Kochurov E.K., Loshkarev E.A., Galeev A.S. Metabolic dysfunction-associated steatotic liver disease (MASLD) and excess body weight: a literature review. Health, Demography, and Ecology of Finno-Ugric Peoples 2025; 3: 35–42. DOI: 10.64111/1994-8921.2025.51.3.007 (in Russian).Suzuki K., Tamaki N., Kurosaki M. et al. Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease. Hepatol Res. 2024; 54 (6): 600–605. DOI: 10.1111/hepr.14011Barritt A.S. 4th, Yu F., Mospan A.R. et al. High concordance between nonalcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease in the TARGET-NASH Real-World Cohort. Am J Gastroenterol. 2024; 119 (8): 1624–1627. DOI: 10.14309/ajg.0000000000002796Zou H., Ma X., Pan W., Xie Y. Comparing similarities and differences between NAFLD, MAFLD, and MASLD in the general U.S. population. Front Nutr. 2024; 11: 1411802. DOI: 10.3389/fnut.2024.1411802Gong H., Liu X., Cheng F. Relationship between non-alcoholic fatty liver disease and cardiac arrhythmia: a systematic review and meta-analysis. J Int Med Res. 2021; 49 (9): 3000605211047074. DOI: 10.1177/03000605211047074Mantovani A., Dauriz M., Sandri D., Bonapace S. et al. Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta-analysis. Liver Int. 2019; 39 (4): 758–769. DOI: 10.1111/liv.14044Cho E.J., Chung G.E., Yoo J.J. et al. Association of nonalcoholic fatty liver disease with new-onset atrial fibrillation stratified by age groups. Cardiovasc Diabetol. 2024; 23 (1): 340. DOI: 10.1186/s12933-024-02408-7Donnellan E., Cotter T.G., Wazni O.M. et al. Impact of nonalcoholic fatty liver disease on arrhythmia recurrence following atrial fibrillation ablation. JACC Clin Electrophysiol. 2020; 6 (10): 1278–1287. DOI: 10.1016/j.jacep.2020.05.023Hung C.S., Tseng P.H., Tu C.H. et al. Nonalcoholic fatty liver disease is associated with QT prolongation in the general population. J Am Heart Assoc. 2015; 4 (7): e001820. DOI: 10.1161/JAHA.115.001820Mantovani A., Rigamonti A., Bonapace S. et al. Nonalcoholic fatty liver disease is associated with ventricular arrhythmias in patients with type 2 diabetes referred for clinically indicated 24-hour Holter monitoring. Diabetes Care. 2016; 39 (8): 1416–1423. DOI: 10.2337/dc16-0091Wong M.Y.Z., Yap J.J.L., Sultana R. et al. Association between non-alcoholic fatty liver disease and subclinical atherosclerosis in Western and Asian cohorts: an updated meta-analysis. Open Heart 2021; 8 (2): e001850. DOI: 10.1136/openhrt-2021-001850Ampuero J., Gallego-Durán R., Romero-Gómez M. Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis. Rev Esp Enferm Dig. 2015; 107 (1): 10–16.Koulaouzidis G., Charisopoulou D., Kukla M. et al. Association of non-alcoholic fatty liver disease with coronary artery calcification progression: a systematic review and meta-analysis. Prz Gastroenterol. 2021; 16 (3): 196–206. DOI: 10.5114/pg.2021.109063Alper A.T., Hasdemir H., Sahin S. et al. The relationship between nonalcoholic fatty liver disease and the severity of coronary artery disease in patients with metabolic syndrome. Turk Kardiyol Dern Ars. 2008; 36 (6): 376–381.Hamaguchi M., Kojima T., Takeda N. et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 2007; 13 (10): 1579–1584. DOI: 10.3748/wjg.v13.i10.1579Bisaccia G., Ricci F., Khanji M.Y. et al. Cardiovascular morbidity and mortality related to non-alcoholic fatty liver disease: a systematic review and meta-analysis. Curr Probl Cardiol. 2023; 48 (6): 101643. DOI: 10.1016/j.cpcardiol.2023.101643Alon L., Corica B., Raparelli V. et al. Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. Eur J Prev Cardiol. 2022; 29 (6): 938–946. DOI: 10.1093/eurjpc/zwab212Ismaiel A., Popa S.L., Dumitrascu D.L. Acute coronary syndromes and nonalcoholic fatty liver disease: "un affaire de coeur". Can J Gastroenterol Hepatol. 2020; 2020: 8825615. DOI: 10.1155/2020/8825615Abosheaishaa H., Hussein M., Ghallab M. et al. Association between non-alcoholic fatty liver disease and coronary artery disease outcomes: A systematic review and meta-analysis. Diabetes Metab Syndr. 2024; 18 (1): 102938. DOI: 10.1016/j.dsx.2023.102938Alexander M., Loomis A.K., van der Lei J. et al. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults. BMJ. 2019; 367: l5367. DOI: 10.1136/bmj.l5367Ichikawa K., Miyoshi T., Osawa K. et al. Incremental prognostic value of non-alcoholic fatty liver disease over coronary computed tomography angiography findings in patients with suspected coronary artery disease. Eur J Prev Cardiol. 2022; 28 (18): 2059–2066. DOI: 10.1093/eurjpc/zwab120Jiang C., Yang Q., Hou X. et al. Assessment of non-alcoholic fatty liver disease in suspected coronary artery disease patients: prognostic value and incremental predictive utility over cardiovascular risk factors and CCTA. BMC Med Imaging 2025; 25: 398. DOI: 10.1186/s12880-025-01919-3Bedogni G., Bellentani S., Miglioli L. et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006; 6: 33. DOI: 10.1186/1471-230X-6-33Kim J.H., Moon J.S., Byun S.J. et al. Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study. Cardiovasc Diabetol. 2020; 19 (1): 51. DOI: 10.1186/s12933-020-01025-4Lee C.H., Han K.D., Kim D.H., Kwak M.S. The repeatedly elevated fatty liver index is associated with increased mortality: a population-based cohort study. Front Endocrinol (Lausanne) 2021; 12: 638615. DOI: 10.3389/fendo.2021.638615Chung G.E., Cho E.J., Yoo J.J. et al. Young adults with nonalcoholic fatty liver disease, defined using the fatty liver index, can be at increased risk of myocardial infarction or stroke. Diabetes Obes Metab. 2022; 24 (3): 465–472. DOI: 10.1111/dom.14597Park J., Kim G., Kim B.S. et al. The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study. Cardiovasc Diabetol. 2022; 21 (1): 53. DOI: 10.1186/s12933-022-01483-yLee C.O., Li H.L., Tsoi M.F. et al. Association between the liver fat score (LFS) and cardiovascular diseases in the national health and nutrition examination survey 1999–2016. Ann Med. 2021; 53 (1): 1065–1073. DOI: 10.1080/07853890.2021.1943514Liu H.H., Cao Y.X., Jin J.L. et al. Liver fibrosis scoring systems as novel tools for predicting cardiovascular outcomes in patients following elective percutaneous coronary intervention. J Am Heart Assoc. 2021; 10 (3): e018869. DOI: 10.1161/JAHA.120.018869Vieira Barbosa J., Milligan S., Frick A. et al. Fibrosis-4 index can independently predict major adverse cardiovascular events in nonalcoholic fatty liver disease. Am J Gastroenterol. 2022; 117 (3): 453–461. DOI: 10.14309/ajg.0000000000001606Sinn D.H., Kang D., Chang Y. et al. Non-alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study. J Gastroenterol Hepatol. 2020; 35 (5): 833–839. DOI: 10.1111/jgh.14856Loosen S., Luedde M., Demir M. et al. An elevated FIB-4 score is not associated with cardiovascular events: a longitudinal analysis from 137 842 patients with and without chronic liver disease. Eur J Gastroenterol Hepatol. 2022; 34 (6): 717–723. DOI: 10.1097/MEG.0000000000002377Gries J.J., Hassan Virk H.U., Wang Z. et al. Outcomes of coronary revascularization in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review. Front Cardiovasc Med. 2025; 12: 1609071. DOI: 10.3389/fvm.2025.1609071Keskin M., Hayıroğlu M.İ., Uzun A.O. et al. Effect of nonalcoholic fatty liver disease on in-hospital and long-term outcomes in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2017; 120 (10): 1720–1726. DOI: 10.1016/j.amjcard.2017.07.107Ali H., Kazmi M., Choi C. et al. In-hospital outcomes of patients with non-alcoholic fatty liver disease who underwent percutaneous coronary intervention: A nationwide inpatient sample analysis. Cureus. 2021; 13 (8): e17338. DOI: 10.7759/cureus.17338Miller A., McNamara J., Hummel S.L. et al. Prevalence and staging of non-alcoholic fatty liver disease among patients with heart failure with preserved ejection fraction. Sci Rep. 2020; 10 (1): 12440. DOI: 10.1038/s41598-020-69013-yPeters A.E., Pandey A., Ayers C. et al. Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT. ESC Heart Fail. 2021; 8 (2): 842–848. DOI: 10.1002/ehf2.13250Mantovani A., Petracca G., Csermely A. et al. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals. Gut 2022; gutjnl-2022-327672. DOI: 10.1136/gutjnl-2022-327672Minhas A.M.K., Bhopalwala H.M., Dewaswala N. et al. Association of non-alcoholic fatty liver disease with in-hospital outcomes in primary heart failure hospitalizations with reduced or preserved ejection fraction. Curr Probl Cardiol. 2023; 48 (8): 101199. DOI: 10.1016/j.cpcardiol.2022.101199Takahashi T., Watanabe T., Shishido T. et al. The impact of non-alcoholic fatty liver disease fibrosis score on cardiac prognosis in patients with chronic heart failure. Heart Vessels. 2018; 33 (7): 733–739. DOI: 10.1007/s00380-017-1113-1McEvoy J.W., McCarthy C.P., Bruno R.M. et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024; 45 (38): 3912–4018. DOI: 10.1093/eurheartj/ehae178Younossi Z.M., Koenig A.B., Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64 (1): 73–84. DOI: 10.1002/hep.28431Ciardullo S., Grassi G., Mancia G., Perseghin G. et al. Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2022; 34 (4): 365–371. DOI: 10.1097/MEG.0000000000002299Song Q., Ling Q., Fan L. et al. Severity of non-alcoholic fatty liver disease is a risk factor for developing hypertension from prehypertension. Chin Med J (Engl). 2023; 136 (13): 1591–1597. DOI: 10.1097/CM9.0000000000002111Song Q.R., Liu S.L., Ling Q.H. et al. Severity of nonalcoholic fatty liver disease is associated with cardiovascular outcomes in patients with prehypertension or hypertension: A community-based cohort study. Front Endocrinol (Lausanne) 2022; 13: 942647. DOI: 10.3389/fendo.2022.942647Huang Q., Yu H., Zhong X. et al. Association between hypertension and nonalcoholic fatty liver disease: a cross-sectional and meta-analysis study. J Hum Hypertens. 2023; 37 (4): 313–320. DOI: 10.1038/s41371-022-00686-wAneni E.C., Oni E.T., Martin S.S. et al. Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk. J Hypertens. 2015; 33 (6): 1207–1214. DOI: 10.1097/HJH.0000000000000532Zhou X.D., Lian L.Y., Chen Q.F. et al. Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLD. J Hepatol. 2026; 84 (2): 254–265. DOI: 10.1016/j.jhep.2025.08.017Gawrieh S., Wilson L.A., Cummings O.W. et al. Histologic findings of advanced fibrosis and cirrhosis in patients with nonalcoholic fatty liver disease who have normal aminotransferase levels. Am J Gastroenterol. 2019; 114 (10): 1626–1635. DOI: 10.14309/ajg.0000000000000388Yin H., Yan Z., Zhao F. Risk factors of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: Systematic review and meta-analysis. Technol Health Care. 2024; 32 (6): 3943–3954. DOI: 10.3233/THC-231331Ng C.H., Wong Z.Y., Chew N.W.S. et al. Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality. Front Cardiovasc Med. 2022; 9: 942753. DOI: 10.3389/fcvm.2022.942753Ye Q., Zou B., Yeo Y.H. et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020; 5 (8): 739–752. DOI: 10.1016/S2468-1253(20)30077-7Lu F.B., Zheng K.I., Rios R.S. et al. Global epidemiology of lean non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2020; 35 (12): 2041–2050. DOI: 10.1111/jgh.15156Souza M., Diaz I., Al-Sharif L. Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals. Hepatol Int. 2024; 18 (5): 1396–1415. DOI: 10.1007/s12072-024-10716-zCheah M.C.C., Crane H., George J. Global prevalence, metabolic characteristics, and outcomes of lean-MAFLD: a systematic review and meta-analysis. Hepatol Int. 2025; 19 (3): 607–618. DOI: 10.1007/s12072-025-10801-xToh J.Z.K., Pan X.H., Tay P.W.L. et al. A meta-analysis on the global prevalence, risk factors and screening of coronary heart disease in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2022; 20 (11): 2462–2473.e10. DOI: 10.1016/j.cgh.2021.09.021Raverdy V., Tavaglione F., Chatelain E. et al. Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease. Nat Med. 2024; 30 (12): 3624–3633. DOI: 10.1038/s41591-024-03283-1Ndumele C.E., Neeland I.J., Tuttle K.R. et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation 2023; 148 (20): 1636–1664. DOI: 10.1161/CIR.0000000000001186Гайсин И.Р. Метаболически-ассоциированная жировая болезнь печени – ключевое звено печеночного континуума. Здоровье, демография, экология финно-угорских народов 2024; 2: 68–73 / Gaisin I.R. Metabolic (dysfunction)-associated fatty liver disease – a key item of liver continuum. Health, Demography, and Ecology of Finno-Ugric Peoples 2024; 2: 68–73 (in Russian).Карпунина Н.С., Хлынова О.В. Неалкогольная жировая болезнь печени и хроническая болезнь почек: случайная связь или две манифестации метаболического синдрома? Экспериментальная и клиническая гастроэнтерология 2024; (8): 123–130. DOI: 10.31146/1682- 8658-ecg-228-8-123-130 / Khlynova O.V., Karpunina N.S. Nonalcoholic fatty liver disease and chronic kidney disease: random connections or two manifestations of metabolic syndrome? Experimental and Clinical Gastroenterology 2024; 8: 123–130. DOI: 10.31146/1682- 8658-ecg-228-8-123-130 (in Russian).Гайсин И.Р., Кочуров Е.К. Новый, кардиогепаторенальный, континуум: часть I. Здоровье, демография, экология финно-угорских народов 2025; 3: 52–60. DOI:10.64111/1994-8921.2025.51.3.010 / Gaisin I.R., Kochurov E.K. A novel, cardiohepatorenal, continuum: part I. Health, Demography, and Ecology of Finno-Ugric Peoples 2025; 3: 52–60. DOI: 10.64111/1994-8921.2025.51.3.010 (in Russian).Theodorakis N., Nikolaou M. From cardiovascular-kidney-metabolic syndrome to cardiovascular-renal-hepatic-metabolic syndrome: proposing an expanded framework. Biomolecules. 2025; 15 (2): 213. DOI: 10.3390/biom15020213Гайсин И.Р. Артериальная гипертензия у беременных – новый кардиоренальный континуум. Терапевтический архив 2012; 84 (1): 48–53 / Gaisin I.R. Hypertension in pregnant women – a novel cardiorenal continuum. Terapevticheskii Arkhiv 2012; 84 (1): 48–53 (in Russian).Гайсин И.Р., Кочуров Е.К. Новый, кардиогепаторенальный, континуум: часть II. Здоровье, демография, экология финно-угорских народов 2025; 4: 39–48. DOI: 10.64111/1994-8921.2025.51.4.009 / Gaisin I.R., Kochurov E.K. The new, cardiohepatorenal, continuum: part II. Health, Demography, and Ecology of Finno-Ugric Peoples 2025; 4: 39–48. DOI: 10.64111/1994-8921.2025.51.4.009 (in Russian).Кочуров Е.К., Гайсин И.Р, Ведёхина А.Н. Поражение почек при спондилоартритах: обзор литературы. Медицина и биотехнологии 2025; 1 (3): 269–285. DOI: 10.15507/3034-6231.001.202503.269-285 / Kochurov E.K., Gaisin I.R., Vedekhina A.N. Kidney Involvement in Spondyloarthritis: A Literature Review. Meditsina i Biotekhnologii = Medicine and Biotechnology 2025; 1 (3): 269–285. DOI: 10.15507/3034-6231.001.202503.269-285 (in Russian).Lazarus J.V., Mark H.E., Villota-Rivas M. et al. The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge? J Hepatol. 2022; 76 (4): 771–780. DOI: 10.1016/j.jhep.2021.10.025Wang M., Wuyun Q., Lian D. et al. Global, regional, and national burden of nonalcoholic fatty liver disease (NAFLD) among people aged 15 to 49 years from 1990 to 2021, with projections to 2050: A systematic analysis based on the 2021 global burden of disease study. Medicine (Baltimore). 2025; 104 (37): e44527. DOI: 10.1097/MD.0000000000044527